A systematic review of ustekinumab in the treatment of atopic dermatitis. (18th August 2018)

• Record Type: Journal Article
• Authors: Pan, Yunlei; Xu, Lina; Qiao, Jianjun; Fang, Hong
• Is Part Of: Journal of dermatological treatment. Volume 29:Number 6(2018)
• Page Start: 539
• Page End: 541
• Publication Date: 2018-08-18
• Subjects: Atopic dermatitis -- ustekinumab -- IL-12 -- IL-23; Skin -- Diseases -- Treatment -- Periodicals; Skin Diseases -- drug therapy -- Periodicals; Skin Diseases -- therapy -- Periodicals; 616.5
• DOI: 10.1080/09546634.2017.1406894
• Languages: English
• ISSNs: 0954-6634

Abstract

Abstract: Aim: Ustekinumab, a human monoclonal IgG1 antibody targeting the p40-subunit shared by interleukin (IL)12 and IL-23, represents a potential treatment for atopic dermatitis (AD). We evaluated the efficacy and safety of ustekinumab in the treatment of AD. Methods: We reviewed the published literature by searching from PubMed, EMBASE, Web of Science and ClinicalTrial.gov then retrieved and analyzed several variables from patients records. Results: Ten studies including eight cases and two RCT, comprising 107 patients, were included in the systematic review. Analysis all studies, a total of 58 patients (54.2%) gained an effective treatment with little adverse events. Conclusions: Ustekinumab is a well-tolerated and safe treatment with no significant difference in effect from placebo in patients with AD. Further, larger randomized controlled trials need to be conducted to identify a suitable regimen for AD and provide more evidence for clinical application.